TG Therapeutics Inc (NASDAQ: TGTX) open the trading on Wednesday, with a bit cautious approach as it glided -1.89% to $13.98, before settling in for the price of $14.25 at the close. Taking a more long-term approach, TGTX posted a 52-week range of $6.46-$35.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 2506.46% for the last half of the decade. Nevertheless, stock’s Earnings Per Share (EPS) this year is -236.11%. This publicly-traded company’s shares outstanding now amounts to $151.42 million, simultaneously with a float of $139.77 million. The organization now has a market capitalization sitting at $2.16 billion. At the time of writing, stock’s 50-day Moving Average stood at $15.07, while the 200-day Moving Average is $13.60.
TG Therapeutics Inc (TGTX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. TG Therapeutics Inc’s current insider ownership accounts for 9.56%, in contrast to 58.75% institutional ownership. According to the most recent insider trade that took place on Mar 13 ’24, this organization’s Director sold 5,000 shares at the rate of 15.94, making the entire transaction reach 79,675 in total value, affecting insider ownership by 108,878. Preceding that transaction, on Mar 12 ’24, Company’s Director sold 22,000 for 15.97, making the whole transaction’s value amount to 351,340. This particular insider is now the holder of 215,229 in total.
TG Therapeutics Inc (TGTX) Earnings and Revenue Records
TG Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -236.11% and is forecasted to reach 0.45 in the upcoming year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Let’s observe the current performance indicators for TG Therapeutics Inc (TGTX). It’s Quick Ratio in the last reported quarter now stands at 5.18. The Stock has managed to achieve an average true range (ATR) of 0.66. Alongside those numbers, its PE Ratio stands at $991.49, and its Beta score is 2.32. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.25.
In the same vein, TGTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.01, a figure that is expected to reach -0.05 in the next quarter, and analysts are predicting that it will be 0.45 at the market close of one year from today.
Technical Analysis of TG Therapeutics Inc (TGTX)
[TG Therapeutics Inc, TGTX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 49.49% While, its Average True Range was 0.62.
Raw Stochastic average of TG Therapeutics Inc (TGTX) in the period of the previous 100 days is set at 15.63%, which indicates a major fall in contrast to 34.12% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 29.89% that was lower than 74.17% volatility it exhibited in the past 100-days period.
